03 March, 2025 in Investor Relations Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
28 February, 2025 in Investor Relations Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
26 February, 2025 in Investor Relations Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
10 February, 2025 in Investor Relations Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
03 February, 2025 in Investor Relations Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
23 January, 2025 in Investor Relations Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
14 January, 2025 in Investor Relations Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
23 December, 2024 in Investor Relations Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
26 November, 2024 in Investor Relations New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
01 November, 2024 in Investor Relations Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
